FABP4 and fatty liver disease: In addition, long-term (8–17 weeks) supplementation of AMF suppresses hepatic steatosis with decreasing lipogenesis-related gene expression, including Cebpa, Fabp4, and Slc27a4 in HFD-fed mice [19,26,27].